MARKET

RLAY

RLAY

Relay Therapeutics, Inc.
NASDAQ
19.74
+0.84
+4.44%
After Hours: 19.78 +0.04 +0.20% 19:49 07/07 EDT
OPEN
18.97
PREV CLOSE
18.90
HIGH
20.20
LOW
18.53
VOLUME
5.15M
TURNOVER
--
52 WEEK HIGH
20.20
52 WEEK LOW
3.025
MARKET CAP
4.26B
P/E (TTM)
-12.6134
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RLAY last week (0629-0703)?
Weekly Report · 1d ago
Relay Therapeutics Chief Corporate Development Officer Peter Rahmer sells 50,000 shares for $954,500
PUBT · 5d ago
Relay Therapeutics Targets NRAS Cancers With New First-in-Human Trial
TipRanks · 5d ago
Biotech Is The Rate Cut Trade In Disguise
Seeking Alpha · 06/29 21:20
Weekly Report: what happened at RLAY last week (0622-0626)?
Weekly Report · 06/29 09:51
Relay Therapeutics President, R&D Donald Bergstrom disposes of 93,456 common shares valued at $1.58 million
PUBT · 06/24 20:10
Absci: Eli Lilly Backs Alopecia Data With Funding, But Risks Remain
Seeking Alpha · 06/24 19:51
As AbbVie eyes Apogee, these biotech stocks earn the highest Quant ratings
Seeking Alpha · 06/22 13:32
More
About RLAY
Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company's lead clinical asset, zovegalisib (RLY-2608), is the pan-mutant selective PI3Ka inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Ka-driven vascular anomalies. Its pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.

Webull offers Relay Therapeutics Inc stock information, including NASDAQ: RLAY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RLAY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RLAY stock methods without spending real money on the virtual paper trading platform.